Roche Pushes Personalization With $2.4Bn Foundation Buy-Out
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.
You may also be interested in...
Roche Diagnostics Sees Data Sourcing, AI and Partnerships As Paving The Way to Personalized Health Care, But Challenges Remain
Two Roche Diagnostics executives outlined the company's vision toward personalized health care. Machine learning, partnerships and data sourcing are key.
The Swiss giant's acquisition of Ignyta to get hold of the latter's closely-watched NSCLC drug entrectinib will potentially trigger an intriguing fight for market share in the near future with Loxo Oncology and Bayer's larotrectinib.
Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.